Evaluate Pharma：2025年第二季度全球生物制药行业展望报告（英文版）

VesiGel is a hydrogel-based sustained-release formulation of the chemotherapy, mitomycin C (MMC) currently being developed for bladder cancer, using Urogen Pharma's proprietary reverse-thermal hydrogel system, RTGel®. The gel formulation, which is liquid when chilled, solidifies upon instillation in the body allowing a slow release of the chemotherapy. In October 2024, UroGen Pharma announced the U.S. Food and Drug Administration (FDA) had accepted the new drug application (NDA) for VesiG